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Abstract
Several medical management approaches have been shown to be effective in preventing breast cancer and
detecting it early among women at elevated risk: 1) prophylactic mastectomy; 2) prophylactic oophorectomy;
3) chemoprevention; and 4) enhanced screening routines. To varying extents, however, these approaches are
substantially underused relative to clinical practice recommendations. This article reviews the existing research
on the uptake of these prevention approaches, the characteristics of women who are likely to use various
methods, and the decision-making processes that underlie the differing choices of women. It also highlights
important areas for future research, detailing the types of studies that are particularly needed in four key
areas: documenting women’s perspectives on their own perceptions of risk and prevention decisions; explicit
comparisons of available prevention pathways and their likely health effects; the psychological, interpersonal,
and social processes of prevention decision making; and the dynamics of subgroup variation. Ultimately, this
research could support the development of interventions that more fully empower women to make informed
and values-consistent decisions, and to move towards favorable health outcomes.
Background
Current risk estimation models enable the identification
of women who are at elevated risk for breast cancer
through genetic testing for BRCA1, BRCA2, and other
mutations, as well as other potential genetic susceptibili-
ties made evident by family histories of the disease.
These high-risk women face a lifetime likelihood of
breast cancer of between 20% and 80% depending on
family history and genetic findings, significantly greater
than the average 12% risk for women in the US. A subset
of high-risk women face additional stresses related to
genetic findings that do not correspond to a very specific
risk estimate, or have unclear clinical implications, due
to limitations of existing genetic science and risk
quantification.
Several risk management options are available to sup-
port women at higher than average risk of breast cancer.
Most of these are significantly underused by women
who may benefit in terms of reduced cancer risk and
cancer-related worry. Only about half of BRCA mutation
carriers undergo the recommended prophylactic oophor-
ectomy [1] and fewer than 5% of the high-risk women
likely to benefit from chemoprevention use it [2, 3].
Underuse may be driven by multiple factors: lack of
physician or patient information or understanding; lack
of clinician confidence discussing preventive interven-
tions or identifying women who could benefit from
them; psychological or social dynamics that shape
women’s preferences, deliberations, or ability to act on
their decisions; and fully informed choice. Ultimately, it
is women who make the choices—often with the help of
health professionals and personal connections—about
which prevention options to implement. These indi-
vidual choices have significant impact on utilization of
prevention options, breast cancer incidence, and
health outcomes. Nevertheless, little is known about
the processes women navigate as they make these
decisions.
This article summarizes what is known and unknown
about the various drivers of women’s decisions about
breast cancer risk management methods. It begins with
a brief overview of breast cancer prevention options for
high-risk women, followed by a review of the current
literature regarding decision making about these op-
tions by specific populations of women, and possible
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explanations for these patterns. This review also high-
lights important areas for future research, which could
support the development of interventions that more
fully empower women to make informed and values-
consistent decisions and contribute to favorable health
outcomes. It focuses solely on the prevention decision
making of women at elevated risk of breast cancer due
to identified genetic mutations or familial history. The
prevention behavior of average risk women, decisions
relevant after a breast cancer diagnosis, and the psycho-
logical sequelae of prevention interventions are outside
the scope of this discussion.
Breast cancer prevention pathways
Women at elevated risk for breast cancer are those who
either have a known predisposing genetic mutation, or
have a family history of breast or related cancers sufficient
to raise calculated lifetime chance of breast cancer above
a certain benchmark—usually 20–25% [4–13]. Studies of
breast cancer patients and early population-based screen-
ing studies suggest that between 10% and 15% of women
with a substantial family history likely carry BRCA1/2 mu-
tations [14, 15], and about half of BRCA mutation carriers
are unaware of this status [16, 17]. Current evidence indi-
cates that specific mutations in other genes (ATM, CDH1,
CHEK2, NBN, NF1, PALB2, PTEN, STK11, and TP53) also
confer increased breast cancer risk, and testing for these
mutations is becoming increasingly available. Positive
findings for these mutations are currently associated with
recommendations to add magnetic resonance imaging
(MRI) screenings and, for a subset of these genes, to con-
sider prophylactic surgery, but other aspects of appropri-
ate clinical management for these patients remain under
investigation [13, 18–20]. Guidelines recommend that
women with a family history of breast or related cancers
be screened, receive genetic counseling and testing if
indicated, and receive counseling to discuss chemopre-
vention, risk-reducing surgery, and enhanced surveil-
lance options if found to meet familial or genetic risk
criteria [13, 21, 22]. Four biomedical prevention options
form the basis for women’s individual prevention pathways.
Bilateral prophylactic mastectomy (BPM; the surgical re-
moval of both breasts for breast cancer risk reduction),
the single most effective prevention method, reduces
breast cancer risk by about 90% [23–31] and breast
cancer-specific mortality by upwards of 80% [25, 26]. It
may not improve overall survival, however, relative to rou-
tine mammography and MRI use, particularly for women
who have had their ovaries removed [27]. Contralateral
prophylactic mastectomy (CPM; surgical removal of the
nonaffected breast for women with unilateral breast can-
cer) has not been shown to improve survival rates, but
may decrease the risk of contralateral cancers in certain
high-risk women; it is considered a clinically appropriate
option for breast cancer patients with known BRCA1/2
mutations, significant family history, or high-risk histology
[32–38].
Prophylactic surgical removal of ovaries and fallopian
tubes (bilateral prophylactic salpingo-oophorectomy;
BPSO) is recommended for all BRCA mutation carriers
between the ages of 35 and 40 years (or when child-
bearing is complete). For this group, it reduces the risk
of ovarian, fallopian tube, or peritoneal cancer by 80%
[39], likely halves the risk of breast cancer [33, 36, 40–43]
(but see [44] for a counter-argument), and strongly re-
duces breast cancer mortality, ovarian cancer mortality,
and all-cause mortality [27, 39]. However, adverse effects
include induction of menopause, as well as increased risk
of cardiovascular disease, osteoporosis, and cognitive im-
pairment. Treatment with hormone replacement therapy
(HRT) is controversial due to increased breast cancer
risk [27, 45].
Two selective estrogen receptor modulators are ap-
proved for use as chemoprevention agents in the US. A
5-year course of tamoxifen by premenopausal women at
elevated risk reduces their risk of breast cancer by 30%
to 50%. Side effects include increased risk of endometrial
cancer and venous thrombosis during the treatment
period, while the protective benefits of chemoprevention
last for at least 20 additional years [23, 46–52]. Raloxi-
fene (approved for postmenopausal women) is estimated
to be 76% as effective as tamoxifen in reducing the risk
of invasive breast cancer, with significantly lower risks of
thromboembolic events and uterine cancers [53–55].
Aromatase inhibitors show substantial promise as che-
moprevention agents but are not yet approved for this
use in the US or Europe; other potential chemopreven-
tion agents including nonsteroidal anti-inflammatory
drugs (NSAIDS), aspirin, metformin, cyclooxygenase-2
(COX-2) inhibitors, and poly-adenosine diphosphate-
ribose polymerase (PARP) inhibitors have shown promise
in early clinical research [27, 53, 56–59].
Enhanced surveillance is designed to facilitate early de-
tection and treatment of breast cancer in women at high
risk. Recommendations include: 1) increasing the fre-
quency of clinical breast examinations to biannual
checks; 2) initiation of radiologic screening at younger
ages, such as 5 to 10 years prior to the youngest age of
breast cancer diagnosis in a woman’s family; 3) annual
bilateral screening mammograms, combined with tar-
geted ultrasound examinations as indicated; and 4) the
addition of breast MRI for women with a lifetime risk of
breast cancer of 20% or greater [13, 60]. These methods
substantially increase the probability of early cancer detec-
tion in high-risk women, but require sustained adherence,
involve regular (and sometimes substantial) expenditures,
and raise distress rates associated with false-positive
tests [61–66].
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Lifestyle changes that reduce the risk of breast can-
cer in the general population are considered wise but
insufficient for those with higher, familial risk [30, 56,
67]. These include increased intake of vegetables, fruit,
and fiber, increased exercise, weight management,
smoking cessation, reductions in alcohol use, pro-
longed lactation, and minimizing exogenous hormone
therapy [56, 68].
It is likely that high-risk women commonly compare
the effectiveness and consequences of methods and con-
sider particular combinations of prevention options.
There is, however, a sparse evidence base for these com-
parisons and combinations [69, 70]. It is known that
BRCA mutation carriers can achieve greater risk reduc-
tion by undergoing both BPM and BPSO than either
alone [27, 71], and that prophylactic surgeries generally
reduce both cancer risk and anxiety about cancer [28].
BPSO is likely the single intervention with the best risk-
benefit ratio for BRCA mutation carriers [72, 73].
Prophylactic surgeries may be more cost-effective than
other methods, but enhanced surveillance yields the
most quality-adjusted life years [74, 75]. Given the ser-
ious ethical and practical impediments to randomized
controlled trials, prospective observational studies that
take into account adherence to chemoprevention and
enhanced surveillance could be useful in comparing
morbidity, mortality, and psychological consequences in
the context of various prevention strategies across
various subgroups of women [30, 76].
Women’s prevention choices
Uptake of prevention methods
Most research on uptake of biomedical prevention
methods pertains specifically to BRCA mutation carriers,
and less is known about women with apparent heredi-
tary risk who are negative for BRCA mutations, those
known to carry other risk-increasing genetic mutations,
and those who have not undergone genetic testing. The
rate of BPSO in BRCA mutation carriers ranges from
55% to 90% in various populations over periods ranging
from 6 months to 10 years after receipt of genetic testing
results [1, 77–81]. BPSO is performed on many addi-
tional women with hereditary risk each year, although
the risk-reduction potential is less certain for women
not known to have a BRCA mutation [42, 82]. Most
studies find the rate of BPM among cancer-free BRCA
mutation carriers to be about 20% and gradually rising
[1, 77, 78, 83, 84], although it varies from as low as 11%
to as high as 50% in specific samples [78, 81]. Overall,
up to 80% of BRCA mutation carriers in some populations
may undergo at least one risk-reducing surgery within
5 years of genetic testing [70], but this rate is likely much
lower in other groups. BPSO is likely more common than
BPM among BRCA mutation carriers because ovarian
cancer treatment has poorer success rates than breast
cancer treatment, because BPSO reduces risk of both
ovarian and breast cancer, and because some women find
mastectomy more psychologically difficult due to its
potential effects on body image and sexuality [85]. CPM
rates have risen substantially in recent decades, mostly
among women who are BRCA-mutation negative or do
not know their genetic status, and who are therefore
unlikely to benefit [32, 38, 41, 43, 82, 86–89]. More than
5% of these women currently undergo CPM even as rates
of contralateral breast cancer and regional breast cancer
recurrence are both dropping; this raises concerns about
surgery-related health risks, the need for new methods of
communication about surgical options, and over-
utilization of health services [42, 82, 89].
Population studies suggest that only 1–5% of women
eligible to use tamoxifen for primary prevention actually
do so [3, 67, 90–92]. Only 15% of BRCA mutation car-
riers approached for a chemoprevention trial enrolled
[2], and only 8.5% of BRCA mutation carriers offered
chemoprevention started such a regimen within 4 years
of receiving genetic test results [77]. These usage rates
fall far short of the proportion of women interested in
chemoprevention, which one study found to be upwards
of 40% [93] of those with familial risk. Chemoprevention
also poses the challenge of long-term adherence: a large
study of women at familial risk found that almost half of
those who started tamoxifen chemoprevention did not
complete the 5-year regimen [59, 94]. Additional studies
are needed to fully understand the barriers to chemopre-
vention use, but they include: research gaps (limited risk
prediction at the individual level and questions about
risk-benefit profiles for specific subgroups); physician
challenges (insufficient knowledge, difficulty identifying
chemoprevention candidates, lack of training and confi-
dence in risk assessment and counseling, and lack of
time); and patient challenges (fear of side effects, predicted
stress associated with chemoprevention, inaccurate or in-
complete information, weighing witnessed experiences
more heavily than statistical probabilities, and concerns
about insurance coverage or cost) [3, 93–101]. It is im-
portant to understand low uptake better and to address
the associated challenges, particularly in light of the recent
review panel estimate that up to 50% of breast cancers
among women at elevated risk could be prevented using
currently available chemoprevention [56].
Between 20% and 50% of BRCA mutation carriers, and
probably more high-risk women without known muta-
tions, engage in surveillance alone, without specific inter-
vention for biomedical risk reduction [70, 77]. Despite the
widespread adoption of this ‘watchful waiting’ approach
and recent increases in the use of screening MRI among
women with familial risk [102], studies indicate that fewer
than 70% of women are adherent to evidence-based
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screening recommendations, and that the use of screening
varies by race and ethnicity [103–106]. Effective screening
also requires access to accurate and personalized infor-
mation about the appropriate screening schedule and
to clinical, radiologic surveillance that is financially and
logistically feasible.
The general relationship between lifestyle factors and
breast cancer has been extensively studied, but the spe-
cific extent to which high-risk women use lifestyle
changes to reduce breast cancer risk has not yet been
explored. Future research should examine women’s
perceptions and use of dietary and exercise changes as
prevention behaviors, and how lifestyle choices relate to
women’s other preventive decisions.
Which women choose which prevention options?
Understanding which women are likely to make particular
prevention choices is a key basis for efforts to facilitate in-
formed, values-consistent, health-protective decisions.
This involves understanding how uptake rates do or do
not fit specific subgroups of women, as well as how psy-
chological and social dynamics may affect the preferences
and actions of individuals. Existing knowledge relevant to
this area comes primarily from retrospective studies, usu-
ally of BRCA1/2 mutation carriers and women who have
completed preventive surgeries. This research is largely
descriptive and correlational, and does not explore
decision-making processes or other factors that affect
women’s preferences and choices on a prospective basis.
Severity of risk, family history, and psychological health
Severity of cancer risk (both diagnosed and perceived)
strongly affects prevention behavior. Higher perceived
risk of breast cancer is positively associated with
considering chemoprevention, BPM, and BPSO among
high-risk women in general [83, 107, 108]. Known BRCA
mutation carriers choose BPM more frequently than
other women at elevated risk, and are more likely to
believe that BPM is the best way to reduce both breast
cancer risk and worry [109]. BRCA mutation carriers
who believe ovarian cancer to be incurable are more
likely to undergo BPSO [110]. Women with BRCA1 and
BRCA2 mutations may behave differently with respect to
BPM and BPSO, but this merits additional investigation
[77, 111]. Among breast cancer patients, those who have
clinical correlates of recurrence (larger tumors, lobular
histology, known BRCA 1/2 mutations) are in fact sig-
nificantly more likely to choose CPM [111, 112]. The
most influential correlates of CPM choice, however, are
not these clinical factors but other patient factors: cancer
worry, socioeconomic factors, and demographic factors
[34, 89, 113].
Several studies point to strong but complex rela-
tionships between family history and surgical choice
[114, 115]. BRCA mutation carriers with a first-degree
family history of breast or ovarian cancer—particularly in
a mother or sister—are more likely to undertake prophy-
lactic surgery, and breast cancer patients with a family his-
tory are less likely to choose breast-conserving surgery
and are more likely to undergo CPM [77, 108, 111]. Future
research might clarify these relationships by disentangling
two possible causes for the effects of family history on sur-
gical choice: objective differences in cancer risk depending
on a woman’s specific family history, and the personal im-
pact of directly witnessing a close relative experiencing
cancer.
Some evidence suggests that women’s psychological
well-being may also affect their prevention choices.
Among women with hereditary risk, BPM is more
often chosen by those who experience high anxiety
and/or exaggerated perceptions of their risk [116].
BRCA mutation carriers with poorer self-perceived
health may be more likely to choose prophylactic sur-
gery [110]. The choice to undergo CPM is also associ-
ated with psychological motivations, including higher
cancer-specific distress, worries about recurrence or
the efficacy of surveillance, and the concerns of signifi-
cant others [34, 117–122].
Demographic characteristics
Existing research indicates that breast cancer morbidity
and mortality, access to treatment, and decisions re-
garding a range of related screening, diagnostic, and
treatment questions all differ substantially by race and
ethnicity [103–106, 123–128]. It is thus likely that
racial-ethnic variation also exists in the processes and
outcomes of women’s prevention decision making. A
few studies support this hypothesis, establishing that
both BPM and CPM are most often chosen by white
BRCA mutation carriers [82], and that African-
Americans are less likely to participate in genetic risk
assessment [129]. It would be helpful to know the ex-
tent to which use of BPSO and chemoprevention differ
by race, how decision making and prevention choices
vary among groups of non-white women, and which
mechanisms (e.g., healthcare access, cultural differences,
relationships to providers) underlie these racial-ethnic
variations.
The significant body of research that relates socioeco-
nomic status (SES) to healthcare access, general preven-
tion behavior, and health outcomes suggests that cancer
prevention decisions may also be systematically related
to SES. However, the sparse research on this potential
relationship has so far yielded conflicting findings on re-
lationships between prevention-related choices and SES
indicators including employment, education, and health
insurance status [82, 130]. The lack of direct attention to
relationships between SES and prevention decisions, and
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the prominence of attention to financial considerations
in the work of patient advocacy organizations [131], also
suggest that this is an area that merits further investiga-
tion. The influence of SES on decision making could op-
erate through both direct mechanisms (e.g., women
considering what they can afford) and indirect mecha-
nisms (e.g., if SES influences the degree to which health-
care providers engage in shared decision making).
Prevention decisions also vary by age. Both BPM and
CPM are associated with younger ages among BRCA
mutation carriers [132], while the choice of BPSO is as-
sociated with older ages [1, 26, 109, 111, 133] (but see
[81] for an exception). The effects of age on chemopre-
vention or enhanced surveillance behavior have not been
well studied, but it is clear that decision making is par-
ticularly complex for young BRCA mutation carriers
who are often single, childless, and not yet confident
making life-altering decisions [134–137].
Prophylactic surgery is more often chosen by BRCA
mutation carriers who have at least one child [112], and
those with multiple children are even more likely to
undergo BPM and/or BPSO [1, 26, 81, 109, 138]. Marital
status could also affect prevention decisions, but this re-
lationship has rarely been investigated [87].
Large geographic differences have been observed in
the uptake of preventive surgeries, across both nations
and subnational regions [81]. Uptake of chemoprevention
and adherence to enhanced surveillance recommenda-
tions could vary geographically as well, and this should be
investigated. The reasons for geographic variation are as
yet unclear and also merit study; potential mechanisms in-
clude cultural differences, provider education or behavior,
availability and policies relevant to specific risk manage-
ment options within a healthcare system, and financial
and geographic access to specialist healthcare and genetic
testing.
Women’s prevention decision making
Information and communications
The acquisition and processing of accurate information
are necessary conditions for appropriate decision making.
Women’s physicians are a trusted but insufficiently
studied source of information about cancer risk and
prevention [139, 140]. Better informed patients make dif-
ferent decisions to others, and a substantial proportion of
variation in the use of medical procedures can be at-
tributed to a lack of solid information transfer from
practitioner to patient, and lack of opportunities for
patients to engage in shared medical decision making
[45, 91, 141–147]. With respect to breast cancer pre-
vention specifically, physicians vary in the provision of
information and recommendations [148], often provide
less information than high-risk women want [149, 150],
frequently struggle to assess individual risk and eligibility
for preventive procedures [67], and have difficulty navigat-
ing variations in patient preferences about the ideal degree
of shared decision making [107, 148]. Intervention design
research is warranted to improve physicians’ confidence in
providing information [151], women’s confidence in
making decisions based on that information, and the over-
all quality of information transfer. Future investigations
should also examine whether confidence in risk informa-
tion differentially affects women’s choices to pursue par-
ticular risk management behaviors.
For women with access to them, genetic counselors
provide more thorough information about risk and pre-
vention than generalist physicians or oncologists, com-
bined with support to process information and make
decisions [152]. Although the health information they
provide can also vary [153], these interactions are associ-
ated with higher uptake of risk reduction methods [154].
Family, friends, patient communities, and survivor groups
also have varied impact on women’s information gathering
and processing [131, 148, 155], but additional research is
needed about the conditions under which these relation-
ships best support health-protective decision making.
Decisional timing and complexity
For many women, prevention decisions are developed
through complex processes that can involve explicit de-
liberation, objective information, intuitive and affective
elements, and/or input from others [149, 156]. Percep-
tions of personal risk and prevention decisions evolve
over a variable period of time [107, 140, 157–159]. Stud-
ies of BRCA mutation carriers who choose prophylac-
tic surgery indicate that they may take several years
to do so [63, 110], and that they are likely to make
quicker decisions if they anticipate choosing surgery
in the event of positive results before genetic testing,
have first-degree relatives with cancer, experience
higher psychological impacts of genetic findings, are
older, have children, and/or experience specific trig-
gering events [133, 160].
Qualitative studies have revealed that women’s concep-
tualizations of risk and prevention differ substantially
from those of healthcare providers [161–163]. These dis-
tinctions reflect decision-making complexities far deeper
than mere incomplete information or irrational decision
making. The difficulty of prevention and surveillance
choices for women at elevated risk likely reflects a range
of normal cognitive patterns described by Daniel Kahne-
man, wherein intuitive and emotional decision making,
shaped by personal experiences and instincts, is usually
dominant over the conscious, analytic style of decision
making. High-risk women report actively striving to
make careful, deliberative breast cancer prevention deci-
sions, but the cognitive dominance of the more reflexive
decision-making mode may make this exceptionally
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difficult unless women have access to both thorough in-
formation and the cognitive skills necessary to process
it [164]. Hesse-Biber and An further describe how pre-
vention decision making in BRCA mutation carriers in-
volves filtering genetic information through a complex
framework of diverse psychological, social, and emo-
tional factors [165]. Other research suggests some of
the specific complexities that may shape women’s
choices (nonlinear movement toward a decision [162];
acting to both maximize survival and preserve a sense
of self [166, 167]; processing cancer experiences of pri-
mary relatives [157, 159, 168]; interpreting BRCA muta-
tions as pressure to act [169]; and experiencing the
uncertainties and interventions associated with elevated
risk) are similar to those associated with breast cancer
itself [96, 145, 163, 168, 170, 171]. These preliminary
observations suggest that deeper attention to the mean-
ings women construct around levels of risk, prevention
options, diseases, and treatments may be an important
element in understanding their decision making.
Emotions
The stress associated with uncertainty is a central part
of coping with health risks, and may be triggered at
many stages of decision making [61, 148, 149]. Cancer-
related worry or anxiety strongly motivates most women
to take preventive action [109, 172–175]; particularly
high levels of worry may also impede adherence to
surveillance recommendations among some groups
[176–178]. Some women are motivated to undertake
preventive action through fear of abandoning their
children, but others avoid surgeries that might cause
their children to worry [140, 159]. Decisions can be
changed or delayed by fear of surgery or side effects
[67, 159]. Women’s decisions are also shaped by aspi-
rations for their future (e.g., desire to have children),
predictions about future emotions, perceived control
over health, self-worth, experiences in high-risk fami-
lies, risk fatigue, and cancer-related stigma [28, 97,
159, 164, 179]. Affective influences merit more
thorough attention, and socio-emotional factors so far
absent from the academic literature may also exert
powerful influence on women’s decisions [164]. For in-
stance, the broad body of research on patient-centered
care, anecdotal news reports, and comments posted in
online support communities all indicate that the desire
to take control of one’s health can be a profound, but as-
yet unstudied, part of the decision-making journey for
women facing elevated risk of breast cancer [131, 180].
Interactions among drivers of prevention choice
Finally, the impact of the drivers of decision making dis-
cussed above may not be consistent across subgroups of
women, and a comprehensive understanding of interactive
effects may be critical to the design of effective decision-
support interventions. Relevant examples can be found in
studies of race and ethnicity in decision making; for in-
stance, subgroups of Asian-American women differ in
their use of mammogram screening by ethnicity, health
insurance, and SES [105, 181]. Minority populations also
include a high proportion of the medically underserved
[182], which suggests that understanding decision making
may require attention not just to individual-level factors,
but also to the communities in which women live and the
resources they can access.
Future research
Many of the most substantial gaps in the research litera-
ture have to do not with breast cancer risk reduction op-
tions themselves, but instead with how women make
sense of and utilize these measures. Key gaps in existing
knowledge of women’s prevention decision making are
summarized in Table 1. Future research should focus on
four key areas.
Table 1 Key gaps in current knowledge concerning breast
cancer prevention decision making by women at elevated risk
• Which prevention options and combinations women consider viable
(prevention pathways)
• Women's reasons for low uptake of biomedical prevention interventions
• Explicit comparisons of prevention options and their effects
• How prevention behavior varies among subgroups of women, who
differ according to:
– Medically-defined or self-perceived level of risk
– Geographical and cultural context
– Race-ethnicity or socioeconomic status
– Access to medical information or care
• Mechanisms that account for variation in prevention choices across
subgroups
• Effects of emotions and psychological factors on women’s prevention
decision making
• Effects of spouses, children, family, and friends on decision making
• Effects of exposure to cancer patients, support groups, or advocacy
organizations on decision making
• Effects of exposure to genetic counseling and quality of
communication with other healthcare providers on decision making
• Effects of previously unstudied factors on decision making: stigma,
self-worth, desire to take control of health, personal exposure to
experience of cancer
• Interactions among various drivers of prevention choice
• How women at elevated risk explain their own decision-making
processes and needs
• Key methods to help women attain informed and empowered
decision making
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Women’s own perspectives
Prior research on women’s use of prevention interven-
tions has been largely quantitative and deductive. This
research has provided a powerful foundation for under-
standing women’s prevention behavior, but has also
missed key dynamics such as the potential roles of finan-
cial resources, social support, and desire to control one’s
health. The ability to support improved decision making
will hinge on accurate understanding of women’s own
perspectives, which can be illuminated by systematic
qualitative research that offers women more space to
articulate perspectives on their own experiences, ratio-
nales, and challenges.
Explicit comparison of prevention pathways
The ability of women to compare their options would be
facilitated by research that explicitly documents the ef-
fects of various choices on physical, psychological, and
social well-being. One potential outcome of such re-
search may be improved decision aids, which have been
shown to positively impact knowledge, expectations,
distress, and decisions among patients facing multiple
medical options with complex pros and cons [183–189].
Initial steps have been made toward developing such
tools for women at elevated risk (particular with respect
to chemoprevention) [185, 190–200], but considerable
work remains to incorporate all possible prevention
pathways, and to consider psychological, social, and
demographic factors in the construction of decision
aids [97].
Processes of decision making
Inductive research from women’s own perspectives may
illuminate previously unstudied processes important to
women’s decisions, and thereby offer new potential ap-
proaches for designing prevention-supportive interven-
tions. At a minimum, these dynamics are likely to
include: psychological factors from cancer-specific dis-
tress and fear for children to the desire to take control
of health; social dynamics of support from spouses, family,
and friends; exposure to cancer patients, survivors, and
advocacy groups; the need to bolster both information
acquisition and skills-building to facilitate deliberative
decision making; and interactions among the drivers of
prevention choice.
Dynamics of subgroup variation
Existing research in and beyond the area of breast can-
cer prevention indicate that decision-making processes
and prevention choices are likely influenced by the
severity of medical risk, geographical context, race-
ethnicity, SES, and access to medical information or
care. These distinctions may have important implications
for tailoring supportive interventions.
Conclusions
One key conclusion of this review is that we must
broaden our research agenda beyond the medical com-
ponents of prevention interventions themselves, to focus
also on social questions and women’s perspectives rele-
vant to breast cancer prevention. Such research will help
resolve crucial mismatches between the biomedical in-
terventions researchers have developed to mitigate can-
cer risk and women’s real-life prevention behavior, and
will ultimately provide critical support for the objective
of preventing breast cancer among women at elevated
risk.
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PTEN: Phosphatase and tensin homolog gene; SES: Socioeconomic status;
STK11: Serine/threonine kinase 11; TP53: Tumor protein p53
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